DCB Taiwan

Development Center for Biotechnology logo
Your Solutions
Pharmaprojects Login image
PHARMAPROJECTS

Global R&D Intelligence - Novel Drug
全球R&D綜合數據 - 創新藥
Product Login
Person standing in front of a presentation screen.
BIOMEDTRACKER

Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
Product Login
Datamonitor Healthcare Login image
DATAMONITOR HEALTHCARE

Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Product Login

Training & Help

We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]

我們提供各產品的使用培訓支持,請點擊下列查閲相關培訓資源,若有特定培訓需求或安排則可聯絡:[email protected]


For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:

若有任何登錄問題,請切換至Meet the Team版面並聯絡對接服務團隊,或可聯絡全球/亞太客服團隊:

Global - [email protected] (English only)

APAC - [email protected] (via English/Chinese)

Require Research Support?
Ask-the-Analyst™

Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.

作爲重點合作夥伴,貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復(工作日),并爲您提供信息收集或專業見解,最終助您做出更快、更明智的業務決策。

Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.

由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持,您的個人資訊與提問内容均會被嚴格保密。

Business professional posing at an office.

 

Latest Monthly Newsletter

Edition: May 2025

 

NEWS & INSIGHTS (incl. Key Themes, Latest Interviews, Recent Reg. Guidance)

  • Notable Theme (Commercial): Biotech companies continue to face difficult choices with access to cash constrained: speaking at Swiss Biotech Day in Basel, Sanofi's R&D chief Houman Ashrafian, who until 2023 was a biotech investor who co-founded nine companies, cautioned them nevertheless not to "squeeze clinical development", as cost-saving at the expense of decent trial data represented a "false economy”.
  • Notable Theme (Commercial): Trump's effort to get pharma companies to offer the prices they charge internationally in the US, often shorthanded as Most Favored Nation (MFN), is getting broad attention because of its significant implications. But while much of the coverage focuses on White House antics, the Pink Sheet has the forethought and global resources to look deeper at the potential impact, particularly in Europe. A trio of recent stories examined how MNF could be a 'game changer' for access, unpacked how difficult higher spending would be to achieve, and considered whether collective procurement could offer a stout defense.
  • Notable Theme (Regulatory): In a display of political authority over the public health apparatus, HHS Secretary Kennedy bypassed the CDC and Advisory Committee on Immunization Practices in changing or eliminating some COVID vaccine recommendations. This should put vaccine sponsors on alert that standard processes involving ACIP making recommendations for use following FDA approval may no longer be followed for other types of vaccines.

 

EDITORIAL CONTENTS (incl. Podcasts, Webinars)

  • Notable Podcast: Drug Fix: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns
  • Notable Webinar: ASCO 2025: Key Insights & Innovations (June 17, 2025)
  • Notable Webinar: Turbulent Seas: 2025 World Preview (July 1, 2025)

 

DEALS & FINANCING (incl. M&As, Licensing, Financing)

  • Notable M&A: Lilly to Acquire SiteOne Therapeutics for up to $1B
  • Notable Licensing: Pfizer Enters into Exclusive $6.15B Licensing Agreement with 3SBio for SSGJ-707 ($1.35B upfront)
  • Notable Financing: GlycoEra Gets $130M in Series B Round

 

KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)

  • Notable Analysis: Daiichi Sankyo | Enhertu | HER2+ Breast Cancer (Approved): “Significant milestone for AstraZeneca and Daiichi Sankyo as Enhertu demonstrates benefit for the first time in early-stage breast cancer patients…”
  • Notable Analysis: Cingulate | CTx-1301 | ADAH (Phase 3): “Positive data from the prematurely terminated Phase III trial assessing CTx-1301 in ADHD bode well for upcoming NDA filing…”
  • Notable Analysis: Regeneron | Itepekimab | COPD (Phase 3): “Mixed results from the leading IL-33 inhibitor, itepekimab, have stirred mixed reactions in the COPD market…”

 

RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)

    • Notable Report: Annual Completed Clinical Trials Report
    • Notable Report: Dealmaking Quarterly Statistics, Q1 2025
    • Notable Report: Financing Quarterly Statistics, Q1 2025
    • Notable Report: Under Pressure: The State of Biopharma in Q1 2025
    • Notable Report: Post-AAN 2025 Conference Report
    • Notable Report: ASCO 2025 Weekend Update
    • Notable Report: The Methodology Trilogy: How to Forecast like a King
    • Notable Report: Patient-based Forecast: Multiple Myeloma
    • Notable Report: Epidemiology Forecast: Chronic Lymphocytic Leukemia (CLL)
    • Notable Report: Wet AMD KOL Interview  US, South #1
    • Notable Report: Epilepsy KOL Interview – France
    • Notable Report: Ovarian Cancer KOL Interview  US, Northeast

 

''

 

Latest Editorial Podcasts